º»¹® ¹Ù·Î°¡±â

·Î±×ÀÎ ¹Ù·Î°¡±â


¾¾¿¡½º¿¤º£¸µÄÚ¸®¾Æ À¯ÇÑȸ»ç ±â¾÷Á¤º¸

¾¾¿¡½º¿¤º£¸µÄÚ¸®¾Æ À¯ÇÑȸ»ç

°ü½É±â¾÷ Ãß°¡Çϰí ä¿ë¼Ò½Ä ¹Þ±â

  • ¿ÏÁ¦ ÀǾàǰ, ÀǾàǰ ¹ÝÁ¦Ç°, ¹é½Å, ÀÇ·á±â±â, ÀǾà¿Üǰ ¹× ±âŸ ÀǾà°ü·ÃÁ¦Ç°ÀÇ °³¹ß, »ý»ê
  • ±â¾÷¸í¾¾¿¡½º¿¤º£¸µÄÚ¸®¾Æ À¯ÇÑȸ»ç
  • ±â¾÷±Ô¸ðÁß¼Ò±â¾÷
  • ´ëÇ¥ÀÚ±è±â¿î
  • ¼³¸³ÀÏ2019³â 1¿ù 14ÀÏ
  • ¸ÅÃâ¾×-
  • »ç¿ø¼ö-
  • Æò±Õ¿¬ºÀ7,788¸¸¿ø
  • ÀÚº»±Ý-

ȸ»ç¼Ò°³

  • ȸ»ç¼Ò°³

CSL Behring is a global leader in

developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people¡¯s lives depend on it, CSL¡¯s R&D fuels the company¡¯s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunology and Neurology, Hematology and Thrombosis, Cardiovascular and Metabolic, Respiratory and Transplant. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.
Product portfolio https://www.csl.com/research-and-development/product-pipeline

  • ÀÎÀç»ó


  • ¿¬Çõ


±â¾÷À§Ä¡

  • ÁÖ¼Ò : ¼­¿ïƯº°½Ã Áß±¸ ¼¼Á¾´ë·Î 136 (ÅÂÆò·Î1°¡,ÆÄÀ̳½½ººôµù) 21Ãþ

µ¿ÀÏ ±â¾÷ÀÌ¶óµµ Å¸Áö¿ª ä¿ëÀÇ °æ¿ì, ȸ»ç ÁÖ¼Ò¿Í Àα٠ÁöÇÏö Á¤º¸°¡ »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.